Core Insights - Mirum Pharmaceuticals is focused on developing therapies for rare liver diseases and is expanding its team through inducement grants to attract key talent [1] - Raymond James has given MIRM a "Strong Buy" rating with a price target of $110, indicating a potential increase of approximately 68.92% from its stock price of $64.67 [2] - The company currently has a negative earnings yield of -1.26% and a negative price-to-earnings (P/E) ratio of -79.19, indicating a lack of profitability [3] Financial Metrics - The price-to-sales ratio is 6.78, and the enterprise value to sales ratio is 6.85, suggesting investors are willing to pay a premium for revenue [3] - The enterprise value to operating cash flow ratio is high at 72.31, indicating potential overvaluation relative to cash flow [3] - The debt-to-equity ratio stands at 1.08, showing a moderate level of debt compared to equity, while the current ratio of 3.31 indicates strong liquidity [3]